Fig. 4: Kaplan–Meier plots of survival in high and low neutrophil-to-lymphocyte ratio (NLR) subgroups of the sintilimab group. | Nature Communications

Fig. 4: Kaplan–Meier plots of survival in high and low neutrophil-to-lymphocyte ratio (NLR) subgroups of the sintilimab group.

From: Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Fig. 4: Kaplan–Meier plots of survival in high and low neutrophil-to-lymphocyte ratio (NLR) subgroups of the sintilimab group.

a Overall survival with NLR at baseline. b Progression-free survival with NLR at baseline. c Overall survival with NLR at 6 weeks post treatment. d Progression-free survival with NLR at 6 weeks post treatment. HR hazard ratio. P-values were based on a two-sided log-rank test.

Back to article page